Skip to main content

Advertisement

Log in

Comparative Study of Liposomal Bupivacaine Versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Several approaches to minimize postoperative pain, nausea, and enhance recovery are available for patients undergoing mastectomy with immediate tissue expander (TE) reconstruction. We compared the effectiveness of intraoperative local infiltration of liposomal bupivacaine (LB) to preoperative paravertebral block (PVB).

Methods

We retrospectively reviewed patients who underwent mastectomy with immediate TE reconstruction between May 2012 and October 2014 and compared patients with preoperative ultrasound-guided PVB to those with intraoperative LB infiltration.

Results

Fifty-three patients (54.6 %) received LB and 44 received PVB. LB was associated with less opioid use in the recovery room (p < 0.001), fewer patients requiring antiemetics (p = 0.03), and lower day of surgery pain scores (p = 0.008). LB also was associated with longer time to first opioid use (p = 0.04). On multivariable analysis controlling for expander placement location, year of surgery, and axillary lymph node dissection (ALND), the only variable that remained statistically significant was lower opioid use in the recovery room for patients with LB (p = 0.03) and day of surgery pain scores approached significance (p = 0.05). There was no difference in the proportion of patients discharged within 36 h of surgery between the groups. Focusing on first cases of the day (where PVBs are performed in the OR) showed average time to skin incision was 15 min shorter in the LB group (p = 0.004).

Conclusions

Local infiltration of LB in patients undergoing mastectomy with immediate TE reconstruction decreases narcotic requirements in the recovery room, shortens preoperative anesthesiology time, and provides similar, if not better, perioperative pain control compared with PVB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Albornoz CR, Bach PB, Mehrara BJ, et al. A paradigm shift in U.S. breast reconstruction: increasing implant rates. Plast Reconstr Surg. 2013;131:15–23.

    Article  PubMed  CAS  Google Scholar 

  2. Vadivelu N, Schreck M, Lopez J, et al. Pain after mastectomy and breast reconstruction. Am Surg. 2008;74:285–96.

    PubMed  Google Scholar 

  3. Quinn AC, Brown JH, Wallace PG, et al. Studies in postoperative sequelae. Nausea and vomiting: still a problem. Anaesthesia. 1994;49:62–5.

    Article  PubMed  CAS  Google Scholar 

  4. Layeeque R, Hochberg J, Siegel E, et al. Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann Surg. 2004;240:608–13.

    PubMed  PubMed Central  Google Scholar 

  5. Strazisar B, Besic N, Ahcan U. Does a continuous local anaesthetic pain treatment after immediate tissue expander reconstruction in breast carcinoma patients more efficiently reduce acute postoperative pain: a prospective randomised study. World J Surg Oncol. 2014;12:16.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Boughey JC, Goravanchi F, Parris RN, et al. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg. 2009;198:720–5.

    Article  PubMed  Google Scholar 

  7. Coopey SB, Specht MC, Warren L, et al. Use of preoperative paravertebral block decreases length of stay in patients undergoing mastectomy plus immediate reconstruction. Ann Surg Oncol. 2013;20:1282–6.

    Article  PubMed  Google Scholar 

  8. Fahy AS, Jakub JW, Dy BM, et al. Paravertebral blocks in patients undergoing mastectomy with or without immediate reconstruction provides improved pain control and decreased postoperative nausea and vomiting. Ann Surg Oncol. 2014;21:3284–9.

    Article  PubMed  Google Scholar 

  9. Aufforth R, Jain J, Morreale J, et al. Paravertebral blocks in breast cancer surgery: is there a difference in postoperative pain, nausea, and vomiting? Ann Surg Oncol. 2012;19:548–52.

    Article  PubMed  Google Scholar 

  10. American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116:248–73.

    Article  Google Scholar 

  11. Chahar, P., Cummings, KC 3rd. LB: a review of a new bupivacaine formulation. J Pain Res. 2012;5:257–64.

    PubMed  PubMed Central  Google Scholar 

  12. Gorfine SR, Onel E, Patou G, et al. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54:1552–9.

    Article  PubMed  Google Scholar 

  13. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28:776–88.

    Article  PubMed  CAS  Google Scholar 

  14. Pacira Pharmaceuticals Inc. EXPAREL (bupivacaine liposome injectable suspension) prescribing information. Pacira Pharmaceuticals Inc.: Parsippany; 2014.

    Google Scholar 

  15. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 6th edn. Glenview: American Pain Society; 2008.

    Google Scholar 

  16. Haas E, Onel E, Miller H, et al. A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation. Am Surg. 2012;78:574–81.

    PubMed  Google Scholar 

  17. Bramlett K, Onel E, Viscusi ER, et al. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release LB, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012;19:530–6.

    Article  PubMed  Google Scholar 

  18. Smoot JD, Bergese SD, Onel E, et al. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study. Aesthet Surg J. 2012;32:69–76.

    Article  PubMed  Google Scholar 

  19. Minkowitz HS, Onel E, Patronella CK, et al. A two-year observational study assessing the safety of DepoFoam bupivacaine after augmentation mammaplasty. Aesthet Surg J. 2012;32:186–93.

    Article  PubMed  Google Scholar 

  20. Onel E, Miller H, Patou G, White PF. EXPAREL, a LB local analgesic, extends pain relief and decreases opioid use. Presented at the Annual Meeting of the American Society of Anesthesiologists, San Diego, CA, October 16–20, 2010.

  21. Dasta J, Ramamoorthy S, Patou G, et al. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012;28:1609–15.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Judy C. Boughey MD.

Additional information

This study was approved by the Institutional Review Board (IRB) at Mayo Clinic, Rochester, MN.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdelsattar, J.M., Boughey, J.C., Fahy, A.S. et al. Comparative Study of Liposomal Bupivacaine Versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction. Ann Surg Oncol 23, 465–470 (2016). https://doi.org/10.1245/s10434-015-4833-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4833-4

Keywords

Navigation